Corcept Therapeutics Incorporated (CORT) vs Exelixis, Inc. (EXEL)
- Corcept Therapeutics Incorporated CORT 110.16 −2.83%
- Exelixis, Inc. EXEL 62.11 −1.15%
Corcept Therapeutics Incorporated and Exelixis, Inc. are both Biotechnology companies. Exelixis, Inc. is the larger, with a market value of $15.6B against $12.3B — 1.3× the size. Exelixis, Inc. trades at the lower P/E: 18.8× against 212×. Corcept Therapeutics Incorporated grew revenue faster over the last twelve months: 16.0% against 9.23%. Exelixis, Inc. has the higher net margin (35.3% vs 6.53%) and the higher return on invested capital (60.5% vs 1.01%). Across the 21 metrics below, Exelixis, Inc. leads on 18 and Corcept Therapeutics Incorporated on 3.
Valuation
Profitability
| Metric | CORT | EXEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.30% | 96.48% | 65.16% |
| Operating margin | 0.77% | 39.88% | 0.00% |
| Net margin | 6.53% | 35.33% | 0.00% |
| Free cash flow margin | 12.87% | 47.55% | 0.00% |
| Return on equity | 8.08% | 44.39% | (56.36%) |
| Return on assets | 6.41% | 33.28% | (48.04%) |
| Return on invested capital | 1.01% | 60.45% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack